These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients. Cooney GF, Lum BL, Meligeni JA, Dunn SP. Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222 [No Abstract] [Full Text] [Related]
3. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral. Ritschel WA. Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110 [Abstract] [Full Text] [Related]
5. Conversion from cyclosporine Sandimmun to cyclosporine neoral in liver transplant patients with cholestasis or external biliary drainage. Farges O, Haddad N, Girault D, Cabiac MD, Samuel D, Bismuth H. Transplant Proc; 1995 Aug; 27(4):2506-7. PubMed ID: 7652905 [No Abstract] [Full Text] [Related]
6. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients. Diliz HS, Olivera MA, Kershenobich D, Mercado MA, Orozco H. Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302 [No Abstract] [Full Text] [Related]
7. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Trull AK, Tan KK, Tan L, Alexander GJ, Jamieson NV. Br J Clin Pharmacol; 1995 Jun; 39(6):627-31. PubMed ID: 7654480 [Abstract] [Full Text] [Related]
9. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application? Haller GW, Winkler M, Bechstein WO, Oldhafer KJ, Ringe B, Maibücher A, Färber L, Pichlmayr R, Neuhaus P. Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211 [No Abstract] [Full Text] [Related]
10. Oral cyclosporine pharmacokinetics in pediatric renal and liver transplant recipients. Cooney GF, Dunn SP, Kaiser B, Kulinsky AV, Mochon M, Heifets M. Transplant Proc; 1994 Oct; 26(5):2779-80. PubMed ID: 7940876 [No Abstract] [Full Text] [Related]
11. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Noble S, Markham A. Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033 [Abstract] [Full Text] [Related]
12. Relative bioavailability of Sandimmune and Sandimmune Neoral in pediatric liver recipients. Superina RA, Strong DK, Acal LA, DeLuca E. Transplant Proc; 1994 Oct; 26(5):2979-80. PubMed ID: 7940940 [No Abstract] [Full Text] [Related]
14. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation. Holmberg C, Laine J, Jalanko H, Leijala M, Hoppu K. Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219 [No Abstract] [Full Text] [Related]
15. Sandimmune Neoral in paediatric liver transplant recipients with malabsorption of cyclosporin A. Atkison PR, Grant DR, Williams SE, Howard J, Wall WJ, Stiller CR. Transplant Proc; 1994 Oct; 26(5):2953-4. PubMed ID: 7940931 [No Abstract] [Full Text] [Related]